Therapy Areas: AIDS & HIV
Novavax achieves effectiveness against original and variant COVID-19 strains in studies in the UK and South Africa
15 March 2021 -

Biotechnology company Novavax Inc (Nasdaq:NVAX) said on Monday that it has achieved the final efficacy of 96.4% against mild, moderate and severe illnesses from the original COVID-19 strain in a pivotal Phase III study its vaccine candidate NVX-CoV2373 in the UK.

Based on the company's randomized, observer-blinded, placebo-controlled clinical phase IIb study of NVX-CoV2373 in South Africa, the efficacy was 55.4% among HIV-negative study participants in a region where the vast majority of the strains are B1.351 escape variants.

In both studies in the UK and South Africa, NVX-CoV2373 demonstrated 100% protection from all hospitalizations and deaths. Both studies met their statistical success criteria. The analysis showed that the vaccine was well tolerated, with a low rate of Serious, Serious (SAEs) and medically associated adverse events on day 35, balanced between vaccine and placebo groups, revealed the company.

According to the company, NVX-CoV2373 is a protein-based vaccine candidate developed from the genetic sequence of SARS-CoV-2. NVX-CoV2373 was developed using its recombinant nanoparticle technology to generate an antigen derived from the coronavirus spike (S) protein. NVX-CoV2373 contains purified protein antigen and cannot replicate nor can it cause COVID-19.



Related Headlines